TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study
Tóm tắt
Taxane-platinum therapy (TP) has replaced platinum-based therapy (PC or PAC, DNA damaging chemotherapy) in the postoperative treatment of ovarian cancer patients; however, it is not always effective. TP53 protein plays a differential role in response to DNA-damaging agents and taxanes. We sought to define profiles of patients who benefit the most from TP and also of those who can be treated with PC. We compared the effectiveness of PC/PAC (n = 253) and TP (n = 199) with respect to tumor TP53 accumulation in ovarian cancer patients with FIGO stage IIB-IV disease; this was a non-randomized retrospective study. Immunohistochemical analysis was performed on 452 archival tumors; univariate and multivariate analysis by the Cox's and logistic regression models was performed in all patients and in subgroups with [TP53(+)] and without TP53 accumulation [TP53(-)]. The advantage of taxane-platinum therapy over platinum-based therapy was seen in the TP53(+), and not in the TP53(-) group. In the TP53(+) group taxane-platinum therapy enhanced the probability of complete remission (p = .018), platinum sensitivity (p = .014), platinum highly sensitive response (p = .038) and longer survival (OS, p = .008). Poor tumor differentiation diminished the advantage from taxane-platinum therapy in the TP53(+) group. In the TP53(-) group PC/PAC was at least equally efficient as taxane-platinum therapy and it enhanced the chance of platinum highly sensitive response (p = .010). However, in the TP53(-) group taxane-platinum therapy possibly diminished the risk of death in patients over 53 yrs (p = .077). Among factors that positively interacted with taxane-platinum therapy in some analyses were endometrioid and clear cell type, FIGO III stage, bulky residual tumor, more advanced age of patient and moderate tumor differentiation. Our results suggest that taxane-platinum therapy is particularly justified in patients with TP53(+) tumors or older than 53 years. In the group of patients ≤53 yrs and with TP53(-) tumors platinum-based therapy is possibly equally efficient. We provide hints for planning randomized trials to verify these observations.
Tài liệu tham khảo
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996, 334: 1-6. 10.1056/NEJM199601043340101.
Trimble EL, Wright J, Christian MC: Treatment of platinum-resistant ovarian cancer. Expert Opin Pharmacother. 2001, 2: 1299-1306. 10.1517/14656566.2.8.1299.
Stuart GC: First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol. 2003, S8-15. 10.1016/S0090-8258(03)00472-4. Suppl 90
Brown R: Cellular responses to DNA damage and cisplatin resistance. Ovarian Cancer 4. Edited by: Sharp F, Blackett T, Leake R, Berek J. 1996, London: Chapmann and Hall Medical, Chapter 22: 205-213.
Sherman SE, Lippard SJ: Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev. 1987, 87: 1153-1181. 10.1021/cr00081a013.
Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C: Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol. 1998, 53: 819-826.
Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993, 74: 957-967. 10.1016/0092-8674(93)90719-7.
Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature. 1979, 277: 665-667. 10.1038/277665a0.
Dumontet C, Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 1999, 17: 1061-1070.
Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 1980, 77: 1561-1565. 10.1073/pnas.77.3.1561.
Rao S, Orr GA, Chaudhary AG, Kingston DG, Horwitz SB: Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl) taxol photolabels a peptide (amino acids 217–231) of beta-tubulin. J Biol Chem. 1995, 270: 20235-20238. 10.1074/jbc.270.34.20011.
Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med. 1996, 2: 72-79. 10.1038/nm0196-72.
Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M: P53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res. 1997, 57: 870-874.
Bellamy CO: p53 and apoptosis. Br Med Bull. 1997, 53: 522-38.
Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996, 56: 689-93.
Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR, Bevilacqua G: p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer. 1997, 75: 230-5.
Ferrandina G, Fagotti A, Salerno MG, Natali PG, Mottolese M, Maneschi F, De Pasqua A, Benedetti-Panici P, Mancuso S, Scambia G: p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer. 1999, 81: 733-40. 10.1038/sj.bjc.6690756.
Baekelandt M, Kristensen GB, Nesland JM, Trope CG, Holm R: Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol. 1999, 17: 2061-
Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF: Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001, 7: 2984-97.
Kupryjanczyk J, Szymanska T, Madry R, Timorek A, Stelmachow J, Karpinska G, Rembiszewska A, Ziolkowska I, Kraszewska E, Debniak J, Emerich J, Ulanska M, Pluzanska A, Jedryka M, Goluda M, Chudecka-Glaz A, Rzepka-Gorska I, Klimek M, Urbanski K, Breborowicz J, Zielinski J, Markowska J: Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer. 2003, 88: 848-854. 10.1038/sj.bjc.6600789.
Smith-Sorensen B, Kaern J, Holm R, Dorum A, Trope C, Borresen-Dale AL: Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer. 1998, 78: 375-381.
Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F: p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol. 2000, 18: 3936-3945.
Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F: A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer. 2001, 92: 738-747. 10.1002/1097-0215(20010601)92:5<738::AID-IJC1249>3.0.CO;2-2.
Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, Yamazaki M, Ito K, Nagamatsu M, Nishizaki T, Asada M, Kameda T, Wakimoto A, Mizutani T, Yamada T, Murata Y: Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett. 2006, 241: 289-300. 10.1016/j.canlet.2005.10.035.
Rakovitch E, Mellado W, Hall EJ, Pandita TK, Sawant S, Geard CR: Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation. Int J Radiat Oncol Biol Phys. 1999, 44: 1119-24.
Gadducci A, Di Cristofano C, Zavaglia M, Giusti L, Menicagli M, Cosio S, Naccarato AG, Genazzani AR, Bevilacqua G, Cavazzana AO: P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel-plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res. 2006, 26: 687-93.
Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW: p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA. 1993, 90: 4961-4965. 10.1073/pnas.90.11.4961.
Dansonka-Mieszkowska A, Ludwig AH, Kraszewska E, Kupryjanczyk J: Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Ann Hum Gene t. 2006, 70: 594-604. 10.1111/j.1469-1809.2006.00257.x.
Van Dyke T: Cancer biology: sense out of missense. Nature. 2005, 434: 287-8. 10.1038/434287a.
Sigal A, Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000, 60: 6788-93.
Kupryjanczyk J, Madry R, Plisiecka-Halasa J, Bar J, Kraszewska E, Ziolkowska I, Timorek A, Stelmachow J, Emerich J, Jedryka M, Pluzanska A, Rzepka-Gorska I, Urbanski K, Zielinski J, Markowska J: TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Br J Cancer. 2004, 91: 1916-1923. 10.1038/sj.bjc.6602238.
Kupryjanczyk J: Why TP53 status does not associate with clinical endpoints in ovarian cancer: facts and hypotheses. Gynecol Oncol. 2006, 100: 5-7. 10.1016/j.ygyno.2005.08.003.
Tavassoli FA, Devilee P, Edited: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2003, World Health Organization Classification of Tumours, IARC Press Lyon
Creasman WJ: Announcement, FIGO stages revisions. Gynecol Oncol. 1988, 35: 125-127.
Partridge EE, Phillips JL, Menck HR: The National Cancer Data Base report on ovarian cancer treatment in United States hospitals. Cancer. 1996, 78: 2236-46. 10.1002/(SICI)1097-0142(19961115)78:10<2236::AID-CNCR28>3.0.CO;2-Z.
Miller AB, Hogestraeten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer. 1981, 47: 207-214. 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6.
Christian MC, Trimble EL: Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol. 1994, S143-150. 10.1006/gyno.1994.1354. Suppl 55
Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW: p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol. 1995, 26: 387-92. 10.1016/0046-8177(95)90138-8.
Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000, 92: 699-708. 10.1093/jnci/92.9.699.
The International Collaborative Ovarian Neoplasm (ICON) Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002, 360: 505-515. 10.1016/S0140-6736(02)09738-6.
Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000, 18: 106-115.
Zhao XD, Zhang Y, He SR, Yang L: Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma. Ai Zheng. 2005, 24: 1542-1545.
Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR, Chi DS: Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol. 2007, 106: 381-7. 10.1016/j.ygyno.2007.04.012.
Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, Tranchand B, Shapira I, AApro M: International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients – an analysis of the medical literature. J Clin Oncol. 2007, 25: 1832-43. 10.1200/JCO.2007.10.6583.
Wasil T, Lichtman SM: Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist. 2005, 10: 602-12. 10.1634/theoncologist.10-8-602.
McGuire WP: Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol. 2003, 21: 133-135. 10.1200/JCO.2003.01.066.
Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997, 272: 17118-25. 10.1074/jbc.272.27.17118.
Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F: A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem. 1999, 274: 23875-82. 10.1074/jbc.274.34.23875.
Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G: Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005, 11: 298-305.
Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997, 100: 1282-93. 10.1172/JCI119642.
Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G: The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res. 2005, 65: 2397-405. 10.1158/0008-5472.CAN-04-3065.
Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, Wilson L, Jordan MA: Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA. 2001, 98: 11737-42. 10.1073/pnas.191388598.
Carles G, Braguer D, Dumontet C, Bourgarel V, Goncalves A, Sarrazin M, Rognoni JB, Briand C: Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Br J Cancer. 1999, 80: 1162-1168. 10.1038/sj.bjc.6690481.
Xia L, Wurmbach E, Waxman S, Jing Y: Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis. Leukemia. 2006, 20: 1009-1016. 10.1038/sj.leu.2404198.
Shakuto S, Fujita F, Fujita M: Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice. Gan To Kagaku Ryoho. 2006, 33: 337-343.
Haldar S, Basu A, Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res. 1997, 57: 229-233.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/27/prepub